Novel Coumarin-Oxadiazole Derivatives Hold Promise for Diabetes Treatment

Strategic Insights -

Researchers from Guizhou Medical University have made new findings in the field of peptide proteins - proinsulin, providing insights into potential treatment options for diabetes. The study, funded by the Guizhou Provincial Basic Research Program and the Innovation and Entrepreneurship Training Program for College Students in Guizhou Province, focused on novel coumarin-oxadiazole derivatives as inhibitors of alpha-glucosidase and protein tyrosine phosphatase 1B (PTP1B). The research identified compound 5j, which exhibited dual inhibitory activity against these enzymes, showing promise for the development of novel anti-hyperglycemic medications.

Key Takeaways:

  • Researchers identified novel coumarin-oxadiazole derivatives as potential inhibitors of alpha-glucosidase and PTP1B, crucial targets for diabetes treatment.
  • Compound 5j exhibited dual inhibitory activity against alpha-glucosidase and PTP1B with IC50 values of 30.57 ± 0.22 μM and 7.58 ± 1.96 μM, respectively.
  • Kinetic experiments showed that compound 5j is a mixed-type inhibitor of alpha-glucosidase.
  • Ultraviolet and infrared spectroscopy experiments demonstrated the ability of compound 5j to induce conformational changes in alpha-glucosidase.
  • Circular dichroism spectroscopy experiments revealed that compound 5j can alter the conformations of both alpha-glucosidase and PTP1B.
  • Molecular docking results showed that compound 5j can embed into the active pockets of both enzymes.
  • The sucrose-loading test demonstrated that compound 5j can reduce post-prandial blood glucose in vivo with low cytotoxicity in normal cells.

Statistics:

  • IC50 value of alpha-glucosidase inhibition for compound 5j: 30.57 ± 0.22 μM
  • IC50 value of PTP1B inhibition for compound 5j: 7.58 ± 1.96 μM
  • Inhibitory activity of compound 5j against both alpha-glucosidase and PTP1B
  • Sucrose-loading test: compound 5j reduced post-prandial blood glucose levels in vivo

Sources:

  • Guangcheng Wang et al., "Design, Synthesis, Kinetic Analysis, Molecular Docking, and Mechanistic Studies of Novel Coumarin-oxadiazole Derivatives As A-glucosidase and Ptp1b Inhibitors." Bioorganic & Medicinal Chemistry, 2025;129.
  • Pergamon-elsevier Science Ltd, The Boulevard, Langford Lane, Kidlington, Oxford OX5 1GB, England. (Elsevier - www.elsevier.com; Bioorganic & Medicinal Chemistry - www.journals.elsevier.com/bioorganic-and-medicinal-chemistry/)
  • NewsRx. Findings from Guizhou Medical University Yields New Findings on Proinsulin (Design, Synthesis, Kinetic Analysis, Molecular Docking, and Mechanistic Studies of Novel Coumarin-oxadiazole Derivatives As A-glucosidase and Ptp1b Inhibitors). Life Science Weekly. November 4, 2025; p 941.